- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04308603
Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing (ANAMETAB-PRO)
Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops Fetalis by Massively Parallel Sequencing
A fetal hydrops, also called a fetal anasarca, is the buildup of fluid in the serosa and / or fetal subcutaneous tissue. The diagnosis is made by ultrasound, possibly from the first trimester of pregnancy.
The etiologies of hydrops can be immune or non-immune. The historically classic immune causes are linked to fetal-maternal alloimmunizations in erythrocyte blood groups. The implementation of systematic prevention of these anti rhesus immunizations since the 1970s has significantly reduced the incidence of immune hydrops Non-immune hydrops (NIH) now represent 90% of fetal hydrops. Known causes of NIH can be classified in several ways depending on the mechanism or organ involved.
The prognosis for NIH is closely linked to the cause. Fetal anemia due to maternal-fetal infections can heal spontaneously or give rise to in utero transfusions. Cardiac rhythm abnormalities are accessible to medical treatment. Chylothorax compressions may benefit from in utero drainage, but chromosomal or metabolic causes cannot benefit from antenatal care. The term of pregnancy in which the hydrops is discovered also has an impact on survival, which however remains poor.
In France, certain pathologies can be considered as particularly serious without the possibility of treatment and give rise to a request for medical termination of pregnancy. This possibility is subject to acceptance by two practitioners who are members of a multidisciplinary prenatal diagnostic center (CPDPN). This preliminary multidisciplinary reflection participates in the development of prenatal counseling with the greatest precision in diagnostic hypotheses. This prenatal advice is essential for a couple on the decision to make a pregnancy in progress but also for future pregnancies, given the 25% risk of recurrence due to the autosomal recessive mode of transmission.
Thus the current screening strategy for inherited metabolic diseases on amniotic fluid is fragmented. The resulting subdiagnosis explains the objective of the study of using the new high throughput sequencing techniques (NGS) in this indication. This approach should make it possible to reduce the number of cases classified as idiopathic, to allow the parents concerned to receive suitable genetic counseling with a view to new pregnancies, and to refine the knowledge of the prenatal epidemiology of these pathologies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: MASSARDIER Jérôme, MD, PhD
- Phone Number: +33 04 27 85 51 81
- Email: jerome.massardier@chu-lyon.fr
Study Contact Backup
- Name: Berthiller Julien
- Phone Number: +33 04 27 85 63 01
- Email: julien.berthiller@chu-lyon.fr
Study Locations
-
-
-
Besançon, France, 25000 Besancon
- Recruiting
- CHU Besançon
-
Contact:
- MOTTET Nicolas, MD,PhD
- Phone Number: +33 03 81 66 81 66
- Email: ncmottet@gmail.com
-
Principal Investigator:
- MOTTET Nicolas, MD,PhD
-
Bordeaux, France, 33076
- Recruiting
- CHU Pellegrin
-
Contact:
- BOUCHGHOUL Hanane, MD,PhD
- Phone Number: +33 05 57 82 25 88
- Email: hanane.bouchghoul@chu-bordeaux.fr
-
Principal Investigator:
- BOUCHGHOUL Hanane, MD,PhD
-
Bron, France, 69500
- Recruiting
- Hôpital Femme Mère Enfant
-
Contact:
- MASSARDIER Jérôme, MD, PhD
- Phone Number: +33 04 27 85 51 81
- Email: jerome.massardier@chu-lyon.fr
-
Contact:
- PERRETON Nathalie
- Phone Number: +33 0427856304
- Email: nathalie.perreton@chu-lyon.fr
-
Principal Investigator:
- MASSARDIER Jérôme, MD, PhD
-
Clermont-Ferrand, France, 63003
- Recruiting
- Hopital D'Estaing
-
Contact:
- GALLOT Denis, PU,PH
- Phone Number: +33 04 73 75 07 50
- Email: dgallot@chu-clermontferrand.fr
-
Principal Investigator:
- GALLOT Denis, PU,PH
-
Dijon, France, 21079
- Recruiting
- Hôpital Le Bocage
-
Contact:
- ROUSSEAU Thierry, MD,PhD
- Phone Number: +33 03 80 29 32 22
- Email: hierry.rousseau@chu-dijon.fr
-
Principal Investigator:
- ROUSSEAU Thierry, MD,PhD
-
La Tronche, France, 38700
- Recruiting
- CHU Grenoble
-
Contact:
- Devillard Françoise, MD,PhD
- Phone Number: +33 04 76 76 72 85
- Email: FDevillard@chu-grenoble.fr
-
Principal Investigator:
- Devillard Françoise, MD,PhD
-
Limoges, France, 87042
- Recruiting
- Chu Limoges
-
Contact:
- COSTE-MAZAUD Perrine, MD,PhD
- Phone Number: +33 05 55 05 66 66
- Email: PERRINE.COSTEMAZEAU@chu-limoges.fr
-
Principal Investigator:
- COSTE-MAZAUD Perrine, MD,PhD
-
Lyon, France, 69004
- Recruiting
- Hopital Croix Rousse
-
Contact:
- FICHEZ Axel, MD, PhD
- Phone Number: +33 04 72 00 15 58
- Email: Axel.fichez@chu-lyon.fr
-
Principal Investigator:
- FICHEZ Axel, MD, PhD
-
Marseille, France, 13000
- Not yet recruiting
- Hopital Nord
-
Contact:
- CHAU Cécile, MD,PhD
- Phone Number: +33 04 91 96 80 00
- Email: cecile.chau@ap-hm.fr
-
Principal Investigator:
- CHAU Cécile, MD,PhD
-
Marseille, France, 13005
- Not yet recruiting
- CHU Marseille Timone
-
Contact:
- SIGAUDY Sabine, MD,PhD
- Phone Number: +33 04 91 96 46 58
- Email: Sabine.SIGAUDY@ap-hm.fr
-
Principal Investigator:
- SIGAUDY Sabine, MD,PhD
-
Montpellier, France, 34295
- Recruiting
- CHU Montpellier
-
Contact:
- FUCHS Florent, PU,PH
- Phone Number: +33 04.67.33.65.32
- Email: f-fuchs@chu-montpellier.fr
-
Principal Investigator:
- FUCHS Florent, PU,PH
-
Nice, France, 06200
- Not yet recruiting
- Hôpital Archet 2
-
Contact:
- ROUZIER Cécile, MD,PhD
- Phone Number: +33 04 92 03 62 43
- Email: rouzier.c@chu-nice.fr
-
Principal Investigator:
- ROUZIER Cécile, MD,PhD
-
Paris, France, 75012
- Recruiting
- APHP Trousseau
-
Contact:
- JOUANNIC Jean-Marie, PU,PH
- Phone Number: +33 01 44 73 52 28
- Email: jean-marie.jouannic@aphp.fr
-
Principal Investigator:
- JOUANNIC Jean-Marie, PU,PH
-
Pierre-Bénite, France, 69310
- Recruiting
- Hopital Lyon Sud
-
Contact:
- THONNON Cyrielle, MD, PhD
- Phone Number: +33 04 78 86 56 66
- Email: cyrielle.thonnon@chu-lyon.fr
-
Principal Investigator:
- THONNON Cyrielle, MD, PhD
-
Saint-Priest-en-Jarez, France, 42270
- Recruiting
- CHU Saint Etienne
-
Contact:
- PRIEUR Fabienne, MD,PhD
- Phone Number: +33 04 77 82 81 16
- Email: Fabienne.Prieur@chu-st-etienne.fr
-
Principal Investigator:
- PRIEUR Fabienne, MD,PhD
-
Toulouse, France, 31059
- Recruiting
- Hôpital Paule de Viguier;
-
Contact:
- DUBUCS Charlotte, MD,PhD
- Phone Number: +33 05 31 15 61 93
- Email: dubucs.c@chutoulouse.fr
-
Principal Investigator:
- DUBUCS Charlotte, MD,PhD
-
Vandœuvre-lès-Nancy, France, 54511
- Recruiting
- CHU de Nancy Brabois,
-
Contact:
- PERDRIOLLE Estelle, MD,PhD
- Phone Number: +33 03 83 34 43 29
- Email: e.perdriolle@gmail.com
-
Principal Investigator:
- PERDRIOLLE Estelle, MD,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patient> 18 years old
- Single Pregnancy
- Progressive pregnancy greater than 11 weeks: Fetal death in utero in a fetus previously known to be a carrier of non Immun Hydrops (NIH) is not an exclusion criterion.
- Presence of an ultrasound defined as follows and confirmed by a multidisciplinary prenatal diagnostic center CPDPN:
- Before 14 weeks: Generalized subcutaneous edema descending to the abdomen, associated or not with peri-visceral effusion
- After 14 weeks: presence of at least 2 of the following criteria: ascites, pleural effusion, pericardial effusion, subcutaneous edema, placental edema, hydramnios.
- Persistent hygroma after 14 weeks of amenorrhea
- Persistent isolated perivisceral effusions without etiologies found
- Patient having an invasive diagnostic sample (amniocentesis)
- Social insured in France
- Patient who signed the informed consent of the study
Exclusion Criteria:
- NIH whose diagnosis is known and confirmed as non-metabolic by a CPDPN
- Non-progressive pregnancy with Fetal Death in utero with normal previous ultrasound monitoring
- Refusal of invasive diagnostic sampling
- Patient under legal protection measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pregnant patient whose fetuses have an antenatal NIH
All pregnant patients whose fetuses have an antenatal revelation of NIH from the first trimester ultrasound scan will be included in this study.
|
Amniotic liquid of each selected patients will be tested by both technic to describe and detect etiological information.
Each patient will be tested using the current procedure with a defined panel of genes as well as with the NGS procedure.
The results of both procedures will be compared.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of fetuses for which a genetic anomaly responsible for antenatal revelation Non Immun Hydrops by Next Generation Sequencing (NGS) analysis
Time Frame: during pregnancy after the 14th week of amenorrhea
|
Proportion of fetuses for which a genetic anomaly responsible for antenatal revelation Non Immun Hydrops can be detected by Next Generation Sequencing (NGS) analysis of the gene panel incriminated in inherited metabolic malformation compared to the proportion of fetuses for which a genetic anomaly has been identified by the technique current standard biochemical.
|
during pregnancy after the 14th week of amenorrhea
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of percentage of etiology detected between the NGS technique and the biochemical technique.
Time Frame: during pregnancy after the 14th week of amenorrhea
|
The percentage of the following etiology of interest (Cardiovascular abnormalities, Chromosomal abnormalities, Haematological abnormalities, infections, Thoracic anomalies, Twin-to-twin transfusion syndromes, Uro-Nephrological Anomalies, Abdominal anomalies, Lymphatic dysplasia, Fetal or placental tumors, osteochondrodysplasias. syndromic, Hereditary Metabolism Diseases) will be assessed and compared between the 2 methods.
|
during pregnancy after the 14th week of amenorrhea
|
time to return the results in days of NGS techniques
Time Frame: during pregnancy after the 14th week of amenorrhea
|
The delay of answer will be defined by the time to return the results by analysis of the panel of genes tested compared to the current standard biochemical technique, measured between the date of completion of the prenatal diagnosis procedure and the date of communication of the results to the parents.
|
during pregnancy after the 14th week of amenorrhea
|
number of technical failure of these new tools of NGS techniques
Time Frame: during pregnancy after the 14th week of amenorrhea
|
Number of technical failures: unable to extract DNA, too little DNA, failed sequencing), and analysis of these failures will be measured and compared to the current standard biochemical technique.
|
during pregnancy after the 14th week of amenorrhea
|
Number of cases where the interpretation of the genetic variants did not lead to a conclusion
Time Frame: during pregnancy after the 14th week of amenorrhea
|
by the number of cases where the interpretation of the genetic variants highlighted did not allow concluding on the imputability for the clinical picture will be assessed of these new tools of NGS techniques
|
during pregnancy after the 14th week of amenorrhea
|
number of week of amenorrhea of gestation
Time Frame: immediately after the child birth
|
number of week of amenorrhea of gestation will be measured
|
immediately after the child birth
|
issue of the pregnancy
Time Frame: immediately after the child birth
|
The percentage of death in utero, the percentage of medical termination of pregnancy, the percentage of neonatal survival and the percentage of pregnancy continued until the end will be calculated
|
immediately after the child birth
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Fetal Diseases
- Pregnancy Complications
- Hemoglobinopathies
- Erythroblastosis, Fetal
- alpha-Thalassemia
- Thalassemia
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Edema
- Metabolism, Inborn Errors
- Hydrops Fetalis
Other Study ID Numbers
- 69HCL19_0501
- 2019-A02338-49 (Other Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Immune Hydrops Fetalis
-
University of California, San FranciscoJohns Hopkins University; Eunice Kennedy Shriver National Institute of Child... and other collaboratorsEnrolling by invitation
-
Thomas Jefferson UniversityRecruitingGenetic Disorders | Nonimmune Fetal Hydrops | Nonimmune Hydrops in NeonateUnited States
-
Chinese University of Hong KongRecruitingHaemoglobin Barts HydropsHong Kong
-
Shanghai First Maternity and Infant HospitalUnknown
-
Obstetrix Medical GroupTerminatedFetal Growth Retardation | Hydrops FetalisUnited States
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationHydrops Fetalis | Birth Defect | Fetal AnomalyUnited States
-
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion...Leiden University Medical CenterUnknownErythroblastosis, Fetal | Erythroblastosis Fetalis, Rh Disease | Erythroblastosis Fetalis Due to RH Antibodies | Erythroblastosis Fetalis Due to IsoimmunizationNetherlands
-
University of California, San FranciscoCalifornia Institute for Regenerative Medicine (CIRM)Enrolling by invitationHemoglobinopathies | Alpha Thalassemia Major | Thalassemia Major | Fetal Hydrops | Hemoglobinopathy; With Thalassemia | Fetal Anemia | Alpha; Thalassemia | Thalassemia Alpha | A-ThalassemiaUnited States
-
Vanderbilt UniversityWithdrawnEndolymphatic Hydrops | Eustachian Tube DysfunctionUnited States
-
The Hospital for Sick ChildrenLabatt Family Heart CentreRecruitingAtrial Flutter | Tachycardia, Supraventricular | Tachycardia, Atrioventricular Nodal Reentry | Tachycardia Atrial | Tachycardia, Reciprocating | Tachycardia, Paroxysmal | Fetal Hydrops | Tachycardia, Atrial EctopicUnited States, Hong Kong, Canada, Netherlands, Sweden, Australia, Brazil, Finland, France, Russian Federation, Spain, Czechia, Switzerland, United Kingdom
Clinical Trials on NON-IMMUNE HYDROPS FETALIS diagnosis
-
University Hospital, MontpellierCompleted
-
University Hospital, AngersRecruitingEssential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageFrance
-
University Hospital, MontpellierABM IndustriesUnknown
-
University Hospital, MontpellierAgence de La BiomédecineActive, not recruitingFragile X Syndrome | Huntington Disease | Myotonic Dystrophy 1France
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsActive, not recruiting
-
Natera, Inc.CompletedSex Chromosome Aberrations | Chromosome 13 Aneuploidy | Chromosome 18 Aneuploidy | Chromosome 21 Aneuploidy | Other MicrodeletionsUnited States
-
Hongkui Yu, MDRecruitingIleocolic IntussusceptionChina
-
Columbia UniversityUnited States Agency for International Development (USAID)Completed
-
Centre Hospitalier Universitaire de Saint EtienneCompletedAutoimmune DiseasesFrance
-
Latin American Cooperative Oncology GroupConselho Nacional de Desenvolvimento Científico e Tecnológico; Instituto do...CompletedNon-small Cell Lung CarcinomaBrazil